Acura Pharmaceuticals (ACUR) Upgraded to Buy by ValuEngine

Acura Pharmaceuticals (OTCMKTS:ACUR) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a report released on Wednesday.

Shares of Acura Pharmaceuticals stock opened at $0.26 on Wednesday. The company has a quick ratio of 0.23, a current ratio of 0.23 and a debt-to-equity ratio of -0.54. Acura Pharmaceuticals has a one year low of $0.10 and a one year high of $0.87.

Acura Pharmaceuticals (OTCMKTS:ACUR) last announced its quarterly earnings data on Tuesday, August 14th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter. The business had revenue of $0.08 million for the quarter.

Acura Pharmaceuticals Company Profile

Acura Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products.

See Also: What are earnings reports?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Acura Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply